JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on August 5, 2004; DOI: 10.1124/jpet.104.073049


0022-3565/04/3113-874-884$20.00
JPET 311:874-884, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.073049v1
311/3/874    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sakai, H.
Right arrow Articles by Tsuchida, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sakai, H.
Right arrow Articles by Tsuchida, E.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Physiological Capacity of the Reticuloendothelial System for the Degradation of Hemoglobin Vesicles (Artificial Oxygen Carriers) after Massive Intravenous Doses by Daily Repeated Infusions for 14 Days

Hiromi Sakai, Yohei Masada, Hirohisa Horinouchi, Eiji Ikeda, Keitaro Sou, Shinji Takeoka, Makoto Suematsu, Masuhiko Takaori, Koichi Kobayashi, and Eishun Tsuchida

Advanced Research Institute for Science and Engineering (H.S., Y.M., K.S., S.T., E.T.), Waseda University, Tokyo, Japan; Departments of Surgery (H.H., K.K.), Pathology (E.I.), and Biochemistry (M.S.), School of Medicine, Keio University, Tokyo, Japan; and East Takarazuka Satoh Hospital (M.T.), Takarazuka, Japan

A hemoglobin vesicle (HbV; diameter 252 ± 53 nm) or liposome-encapsulated Hb is an artificial oxygen carrier developed for use as a transfusion alternative, and its oxygen-transporting capacity has been well characterized, although critical physiological compartments for the Hb degradation after a massive infusion of HbV and the safety outcome remain unknown. In this study, we aimed to examine the compartments for its degradation by daily repeated infusions (DRI) of HbV, focusing on its influence on the reticuloendothelial system (RES). Male Wistar rats intravenously received the HbV suspension at 10 ml/kg/day for 14 consecutive days. The cumulative infusion volume (140 ml/kg) was equal to 2.5 times the whole blood volume (56 ml/kg). The animals tolerated the DRI well and survived, and body weights continuously increased. One day after DRI, hepatosplenomegaly occurred significantly through the accumulation of large amounts of HbV. Plasma clinical chemistry was overall normal, except for a transient elevation of lipid components derived from HbV. These symptoms subsided 14 days after DRI. Hemosiderin deposition and up-regulation of heme oxygenase-1 coincided in the liver and spleen but were not evident in the parenchyma of these organs. Furthermore, the plasma iron and bilirubin levels remained unchanged, suggesting that the heme-degrading capacity of the RES did not surpass the ability to eliminate bilirubin. In conclusion, phospholipid vesicles for the encapsulation of Hb would be beneficial for heme detoxification through their preferential delivery to the RES, a physiological compartment for degradation of senescent RBCs, even at doses greater than putative clinical doses.


Received June 21, 2004; accepted August 4, 2004.

Address correspondence to: Prof. Eishun Tsuchida, Advanced Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan. E-mail: eishun{at}waseda.jp




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
K. Taguchi, Y. Urata, M. Anraku, T. Maruyama, H. Watanabe, H. Sakai, H. Horinouchi, K. Kobayashi, E. Tsuchida, T. Kai, et al.
Pharmacokinetic Study of Enclosed Hemoglobin and Outer Lipid Component after the Administration of Hemoglobin Vesicles as an Artificial Oxygen Carrier
Drug Metab. Dispos., July 1, 2009; 37(7): 1456 - 1463.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. A. Plock, C. Contaldo, H. Sakai, E. Tsuchida, M. Leunig, A. Banic, M. D. Menger, and D. Erni
Is hemoglobin in hemoglobin vesicles infused for isovolemic hemodilution necessary to improve oxygenation in critically ischemic hamster skin?
Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2624 - H2631.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H. Sakai, P. Cabrales, A. G. Tsai, E. Tsuchida, and M. Intaglietta
Oxygen release from low and normal P50 Hb vesicles in transiently occluded arterioles of the hamster window model
Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2897 - H2903.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.